Literature DB >> 24133582

Clinicopathological study of gene rearrangement and microRNA expression of primary central nervous system diffuse large B-cell lymphomas.

Jinfeng Zheng1, Jiagang Xu, Shufang Ma, Xiyan Sun, Ming Geng, Lin Wang.   

Abstract

We studied the clinicopathological and imaging characteristics of primary central nervous system diffuse large B-cell lymphomas (PCNS-DLBCL). Imaging, pathologic histology, and immunohistochemical staining characteristics were analyzed, and the immunoglobulin heavy and light chain gene rearrangement of 25 PCNS-DLBCL cases was examined. MicroRNA was extracted from 10 cases each of PCNS-DLBCL, extracerebral germinal center DLBCL (GC-DLBCL), and extracerebral non-GC-DLBCL (NGC-DLBCL); we conducted chip hybridization and comparatively analyzed the difference among the three. PCNS-DLBCLs typically involved no less than two cerebral lobes (10/25); the frontal lobe was affected most often (6/25). Target-shaped structures were observed in all PCNS-DLBCLs due to the proliferation of centroblast-like large lymphocytes surrounding the vessels. There was strong and diffuse immunostaining for CD20 and CD79a, and negative immunostaining for CD3, CD5, CD23, and cyclin D1 for all PCNS-DLBCLs. The percentage of cells with nuclear positivity for anti-Ki67 antibody ranged 50-90% (mean, 80%). Three, 19, and 22 PCNS-DLBCLs were CD10-, Bcl-6-, and melanoma ubiquitous mutated 1-positive, respectively. Twenty-four PCNS-DLBCLs were B-cell monoclonal. MicroRNA hybridization showed that 788 PCNS-DLBCL microRNAs/segments increased to at least twice that of NGC-DLBCLs, and 401 PCNS-DLBCL microRNAs/segments declined to less than half of that of NGC-DLBCLs. Six hundred and eleven PCNS-DLBCL microRNAs/segments increased to at least twice that of GC-DLBCLs, and 229 PCNS-DLBCL microRNAs/segments declined to less than half of that in GC-DLBCLs. PCNS-DLBCL typically affected multiple sites, tended to occur in older men, arose from activated B cells, had high B-cell monoclonality; its microRNA expression differed from that of NGC-DLBCL and GC-DLBCL.

Entities:  

Keywords:  Central nervous system; diffuse large B-cell lymphoma; gene rearrangement; microRNA

Mesh:

Substances:

Year:  2013        PMID: 24133582      PMCID: PMC3796226     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  11 in total

1.  Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936.

Authors:  P A S Evans; Ch Pott; P J T A Groenen; G Salles; F Davi; F Berger; J F Garcia; J H J M van Krieken; S Pals; Ph Kluin; E Schuuring; M Spaargaren; E Boone; D González; B Martinez; R Villuendas; P Gameiro; T C Diss; K Mills; G J Morgan; G I Carter; B J Milner; D Pearson; M Hummel; W Jung; M Ott; D Canioni; K Beldjord; C Bastard; M H Delfau-Larue; J J M van Dongen; T J Molina; J Cabeçadas
Journal:  Leukemia       Date:  2006-12-14       Impact factor: 11.528

2.  Primary central nervous system lymphoma: a study of clinicopathological features and trend in western India.

Authors:  S Pasricha; A Gupta; J Gawande; P Trivedi; D Patel
Journal:  Indian J Cancer       Date:  2011 Apr-Jun       Impact factor: 1.224

3.  A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines.

Authors:  Rachel E Culpin; Stephen J Proctor; Brian Angus; Stephen Crosier; John J Anderson; Tryfonia Mainou-Fowler
Journal:  Int J Oncol       Date:  2010-08       Impact factor: 5.650

4.  Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system.

Authors:  Alexander Baraniskin; Jan Kuhnhenn; Uwe Schlegel; Andrew Chan; Martina Deckert; Ralf Gold; Abdelouahid Maghnouj; Hannah Zöllner; Anke Reinacher-Schick; Wolff Schmiegel; Stephan A Hahn; Roland Schroers
Journal:  Blood       Date:  2011-01-03       Impact factor: 22.113

5.  Epigenetic down-regulation of the tumor suppressor gene PRDM1/Blimp-1 in diffuse large B cell lymphomas: a potential role of the microRNA let-7.

Authors:  Kui Nie; Taotao Zhang; Hatim Allawi; Mario Gomez; Yifang Liu; Amy Chadburn; Y Lynn Wang; Daniel M Knowles; Wayne Tam
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

6.  Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma.

Authors:  Jan-Lukas Robertus; Geert Harms; Tjasso Blokzijl; Marije Booman; Daphne de Jong; Gustaaf van Imhoff; Stefano Rosati; Ed Schuuring; Philip Kluin; Anke van den Berg
Journal:  Mod Pathol       Date:  2009-03-13       Impact factor: 7.842

7.  Most primary central nervous system diffuse large B-cell lymphomas occurring in immunocompetent individuals belong to the nongerminal center subtype: a retrospective analysis of 31 cases.

Authors:  Eyas M Hattab; Sarah E Martin; Sohaib M Al-Khatib; William J Kupsky; Gail H Vance; Ryan A Stohler; Magdalena Czader; Mousa A Al-Abbadi
Journal:  Mod Pathol       Date:  2009-11-20       Impact factor: 7.842

8.  Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas.

Authors:  Raquel Malumbres; Kristopher A Sarosiek; Elena Cubedo; Jose W Ruiz; Xiaoyu Jiang; Randy D Gascoyne; Robert Tibshirani; Izidore S Lossos
Journal:  Blood       Date:  2008-12-01       Impact factor: 22.113

9.  Evaluation and validation of total RNA extraction methods for microRNA expression analyses in formalin-fixed, paraffin-embedded tissues.

Authors:  Martina Doleshal; Amber A Magotra; Bhavna Choudhury; Brian D Cannon; Emmanuel Labourier; Anna E Szafranska
Journal:  J Mol Diagn       Date:  2008-04-10       Impact factor: 5.568

Review 10.  Primary central nervous system lymphoma.

Authors:  Sharathkumar Bhagavathi; Jon D Wilson
Journal:  Arch Pathol Lab Med       Date:  2008-11       Impact factor: 5.534

View more
  5 in total

Review 1.  Role of microRNAs in primary central nervous system lymphomas.

Authors:  Xin Yu; Zheng Li; Jianxiong Shen; Matthew T V Chan; William Ka Kei Wu
Journal:  Cell Prolif       Date:  2016-03-16       Impact factor: 6.831

2.  Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma.

Authors:  Franziska S Thaler; Sarah A Laurent; Marion Huber; Matthias Mulazzani; Martin Dreyling; Uwe Ködel; Tania Kümpfel; Andreas Straube; Edgar Meinl; Louisa von Baumgarten
Journal:  Neuro Oncol       Date:  2017-11-29       Impact factor: 12.300

3.  APRIL and BAFF: novel biomarkers for central nervous system lymphoma.

Authors:  Matthias Mulazzani; Marion Huber; Sabine Borchard; Sigrid Langer; Barbara Angele; Elisabeth Schuh; Edgar Meinl; Martin Dreyling; Tobias Birnbaum; Andreas Straube; Uwe Koedel; Louisa von Baumgarten
Journal:  J Hematol Oncol       Date:  2019-10-15       Impact factor: 17.388

4.  miR-370 Sensitizes TMZ Response Dependent of MGMT Status in Primary Central Nervous System Lymphoma.

Authors:  Xinwei Li; Xueying Xu; Keng Chen; Haijian Wu; Yirong Wang; Shuxu Yang; Kun Wang
Journal:  Pathol Oncol Res       Date:  2019-02-02       Impact factor: 3.201

5.  Diagnosis, prognosis and treatment of primary central nervous system lymphoma in the elderly population (Review).

Authors:  Yanxia Liu; Qingmin Yao; Feng Zhang
Journal:  Int J Oncol       Date:  2021-02-01       Impact factor: 5.650

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.